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Abstract
Background: Tractional retinal detachment with or without secondary tear is a rare complication reported in less
than 0.5% of in eyes treated for retinoblastoma. Pars plana vitrectomy (PPV) in eyes with history of retinoblastoma
has been associated with a significant risk for recurrence, extraocular spread, and systemic metastases. We report
here the successful management by PPV under melphalan irrigation of 2 children presenting with tractional retinal
detachment after retinoblastoma therapy and scleral buckle surgery.
Case presentation: A 7-year-old girl with a history of bilateral retinoblastoma (group D) presented with light
perception best-corrected visual acuity (BCVA) and tractional retinal detachment (RD) in her left eye, 3 years after
the last intra-arterial chemotherapy (IAC) injection. Moreover, she had history of left eye rhegmatogenous RD
treated by scleral buckle 1 month after the last IAC and cataract surgery 12 months later. PPV associated with
retinectomy, laser photocoagulation and silicone oil tamponade was performed. Silicone oil was removed 4months
later. Fifteen months after PPV, BCVA had increased to 20/32 without recurrence of RD and no evidence of tumor
activity. A 7-year-old boy with a history of unilateral retinoblastoma (group D) in his left eye presented with
rhegmatogenous RD 21 months after the last treatment for retinoblastoma. Scleral buckle surgery was performed,
but 3 weeks later the patient presented with tractional RD associated with proliferative vitreo-retinopathy. BCVA was
counting fingers. PPV associated with membrane peel, laser photocoagulation and silicone oil tamponade was
performed. Silicone oil was removed after 5 months followed by cataract surgery 5 months later. Twenty months
after PPV, BCVA was 20/20 and there was no sign of tumor recurrence.
Conclusions: PPV under melphalan irrigation, with retinectomy, if necessary, and silicone oil tamponade, allows
anatomical and functional improvement in eyes with history of retinoblastoma and scleral buckling developing
tractional RD.
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Background
Serous retinal detachment (RD) is a frequent finding in
eyes with retinoblastoma at presentation, commonly
caused by tumor-related exudation and usually com-
pletely resolving after tumor regression. Transient spon-
taneously resolving RD can also follow or worsen after
rapid tumor regression. In some instances, however, eye-
preserving retinoblastoma management can be compli-
cated by secondary rhegmatogenous and/or tractional
RD. Rhegmatogenous RD has been reported in 1% [1, 2]
to 6% [3, 4] of the cases, mostly due to atrophic retinal
holes. Tractional retinal detachment with or without
secondary tear remains a rare complication reported in
less than 0.5% of cases [1]. Left untreated, such detach-
ments may compromise further tumor control and/or vi-
sion and globe preservation.
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Intraocular surgery in the context of retinoblastoma is
feared because of the risk of tumor spread. Secondary
RD in eyes with retinoblastoma are preferentially man-
aged with an external approach, as scleral buckle surgery
[5–7] or enucleation [8]. Pars plana vitrectomy has been
associated with a significant risk for tumor relapse,
extraocular spread and systemic metastases [9], and thus
reserved for selected cases with no other alternative for
restoring visual function [10]. Although no consensus
exists, usually a 6 to 18 month disease-free follow-up is
preferred before considering scleral buckling with exter-
nal drainage or vitrectomy [1, 2, 11].. Management of re-
current RD in retinoblastoma eyes has not been further
reported.
We report here the successful management of trac-
tional retinal detachment with PPV under melphalan ir-
rigation in 2 children treated for retinoblastoma and
with previous scleral buckling surgery.
Case presentation
Case 1
A 4-year-old girl with bilateral International Intraocular
Retinoblastoma Classification (IIRC) [12] group D retino-
blastoma diagnosed at the age of 20months was treated
with intraarterial injections of combined melphalan and
topotecan for a relapse in the left eye. Previous treatments
of that eye included 2 cycles of systemic chemotherapy
(carboplatin, etoposide), 2 intraarterial and 10 intravitreal
melphalan injections as well as numerous focal treatments
(cryotherapy and thermotherapy). After the third intraar-
terial injection, she developed a total rhegmatogenous RD
secondary to the formation of an atrophic hole at the basis
of the regressed relapse. Scleral buckling without drainage
but with an intraoperative anterior chamber tap to allow a
sufficient tightening of the band was done, resulting in a
complete reattachment of the retina. One year later, she
developed a cataract impeding the fundus view and under-
went lens aspiration with posterior capsulorhexis, anterior
vitrectomy and intracapsular lens implantation. Two and
a half years after cataract surgery, at the age of 7, vision in
that eye suddenly decreased to light perception. Fundus
examination showed a total macula-off tractional retinal
detachment with no identifiable retinal break (Fig. 1 a and
c). PPV under melphalan perfusion (5 μg/ml) was per-
formed. The exclusively tractional nature of the detach-
ment originating from retinal dragging by the tumor scar
was confirmed intraoperatively, since no retinal break was
identified, and subretinal fluid could not be evacuated
after perfluorocarbon liquid injection. To allow the retina
to re-applicate, a retinectomy was created around the
Fig. 1 a-c: Fundus photograph and optical coherence tomography of a 7-year-old girl with history of retinoblastoma and scleral buckle surgery
for RRD, presenting 3.4 years later with total tractional retinal detachment in her left eye. BCVA was light perception. b-d: Fundus photograph and
optical coherence tomography of the same patient 12 months after pars plana vitrectomy under melphalan irrigation, retinectomy, laser and
silicone oil tamponade for 4 months. BCVA increased to 20/40
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tumor scar, followed by laser photocoagulation and sili-
cone oil tamponade. Cytologic examination of the vitrec-
tomy fluid did not find any malignant cells. Silicone oil
was removed 4months later. At a 15-month post vitrec-
tomy follow-up, the child had remained relapse- and
metastasis-free without recurrence of RD and a best-
corrected visual acuity (BCVA) of 20/32 in the vitrecto-
mized eye (Fig. 1 b and d).
Case 2
A boy diagnosed with unilateral IIRC group D retino-
blastoma at the age of 5 was successfully treated with
3 cycles of intravenous chemotherapy (carboplatin,
etoposide) as well as 8 intravitreal and 6 intracameral
melphalan injections. At the age of 7, 21 months after
the last tumor treatment, he presented with sudden vi-
sion decrease in the affected left eye. BCVA was 20/
250. Fundus examination showed a total macula-off
retinal detachment due to a large tear next to the
tumor scar. Scleral buckling without drainage was per-
formed but the retina failed to reapplicate despite ap-
propriate indentation of the buckle, as proliferative
vitreoretinopathy (PVR) developed three weeks later,
particularly involving the macula (Fig. 2a) and indu-
cing tractional retinal detachment. BCVA decreased to
counting fingers. He underwent PPV under melphalan
(5 μg/ml) perfusion with membrane peel, additional
laser photocoagulation around the retinal tear and sili-
cone oil tamponade. Cytologic examination of vitrec-
tomy fluid was negative for malignant cells. Silicone
oil removal was performed 5 months later, and cata-
ract surgery with posterior capsulorhexis and posterior
chamber intraocular lens implantation was performed
10 months later. At 20-month post vitrectomy follow-
up, the child had remained relapse- and metastasis-
free, with no recurrence of retinal detachment and a
BCVA of 20/20 (Fig. 2 b, c).
Discussion and conclusions
We described here 2 unusual cases of tractional retinal
detachment after retinoblastoma treatment, and scleral
buckle surgery for RRD, that were successfully managed
by PPV under melphalan irrigation.
Secondary RD occurring during treatment of retino-
blastoma is to date a rarely reported complication but
this may change in the future as more advanced cases
are now tried to be salvaged. Rhegmatogenous RD due
to an atrophic hole/or a horsehoe tear have been re-
ported after different treatment modalities including
intravenous chemotherapy, external beam radiotherapy
or plaque brachytherapy with the role of focal treat-
ments, as laser photocoagulation or cryotherapy, being
Fig. 2 a: Fundus photograph of a 7-year-old boy with history of retinoblastoma presenting with total tractional retinal detachment and
proliferative vitreo-retinopathy in his left eye after scleral buckle surgery performed 21months after the last tumor treatment. BCVA was counting
fingers. b-c: Fundus photograph and optical coherence tomography of the same patients 14 months after pars plana vitrectomy under melphalan
irrigation, membrane peel, laser photocoagulation and silicone oil tamponade for 5 months. BCVA increased to 20/32
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emphasized [1, 2, 13]. Recently, a greater prevalence of
this complication was found in eyes treated with intraar-
terial chemotherapy with or without focal treatments
compared to those treated with intravenous chemother-
apy and/or external irradiation (6% versus 1%) [3] attrib-
uted by the authors to the rapid tumor regression and
the atrophic hole formation at the basis of the tumor ne-
crosis after intraarterial chemotherapy. RD of tractional
origin occur even less frequently, and have only been re-
ported in a few cases [1, 10].
To date there is no consensus on the best technique nor
the acceptable disease-free interval to manage secondary
RD in cases of retinoblastoma. First concern should be to
rule out an active tumor as part of the detachment under-
lying mechanism or as concomitant feature at time of the
complication diagnosis. Whereas scleral buckling is an ap-
propriate option for rhegmatogenous RD [2, 14] extensive
tractional RD can only be successfully managed with intra-
ocular procedure [1, 2, 6, 10]. We reported here 2 cases of
tractional RD successfully managed by PPV. In the first
case, tractional forces exerted by the tumor scarring process
induced retinal pulling and detachment without evidence
of retinal break. A large retinectomy performed around the
tumor scar allowed retinal reapplication. Retinectomy has
been previously reported in two retinoblastoma eyes [14]
with successful anatomical results. However, retinectomy in
children should be restricted to cases with no other option
for retinal reapplication, such as Case 1, where traction
from the tumor scar induced a recurrence of RD after pre-
vious scleral buckling procedure. The second patient pre-
sented first with a rhegmatogenous RD that was also
treated by scleral buckle surgery. PPV was performed due
to the development of PVR affecting the macula. However,
the large retinal break localized at the tumor edges, makes
us suppose that it could be secondary to the tractional
forces exerted by the tumor scarring process inducing ret-
inal pulling, as in the first case, but more severe resulting in
a secondary tear. Retinal breaks often occur at the edge of
hard calcified retinoblastoma scars, resulting in an irregular
shape and hardness of the break edge, that could be difficult
to treat with scleral buckling without combined vitrectomy
[15], especially if extensive PVR is already present [6].
Additionally, PPV was performed under melphalan perfu-
sion (5 μg/ml), to increase the safety of the procedure (by
preventing a potential active tumor spread through the
scleral ports and/or the choroid), at a dose that was proved
non-toxic for the retina in a rabbit model and in 3 retino-
blastoma patients [14, 16, 17].
Recovery of visual acuity was seen in both patients,
even though spectral-domain optical coherence
tomography of the macula at the last follow-up
showed a slightly atrophic fovea with alterations on
photoreceptor and retinal pigment epithelium layers
in Case 1.
In conclusion, pars plana vitrectomy under melphalan
irrigation, with retinectomy, if necessary, and silicone oil
tamponade is a reasonable treatment option in eyes with
controlled retinoblastoma developing tractional RD after
rhegmatogenous RD treated with scleral buckle.
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